专家视角:难治性炎性肌病的治疗管理
本文讨论特发性炎性肌病(IIM)中难治性病例的管理策略,提出应系统评估残留症状源于持续炎症还是既往损伤,并确认诊断是否正确;在确认持续炎症后需调整治疗,自身抗体分型可能有助于指导治疗选择。
要点
- 难治性IIM管理第一步:区分残留症状源于持续炎症还是炎症前损伤,建议重新诊断评估。
- 对残留肌无力患者,需确认肌炎诊断是否正确或是否存在其他潜在肌肉疾病。
- 确认组织持续炎症后应调整治疗,自身抗体分型可能帮助指导治疗选择。
核心结论
- 难治性IIM的管理需系统评估治疗无反应的原因,以指导疾病管理。
- 自身抗体分型可能有助于识别不同治疗反应的IIM亚组。
研究设计与样本
- 本文为专家视角综述,未报告系统检索范围或样本量。
主要发现
- IIM患者对糖皮质激素及甲氨蝶呤或硫唑嘌呤等一线免疫抑制治疗反应不一,部分患者症状在肌肉、皮肤和肺部持续存在。
- 指导难治性IIM治疗策略的对照试验很少。
- 不同患者亚组及不同器官表现可能对不同治疗有不同反应。
- 开放研究和病例系列的新出现数据支持不同自身抗体定义亚组的治疗反应存在差异。
临床怎么用
- 第一步应通过第二次诊断检查判断残留症状源于持续炎症还是炎症前损伤。
- 对残留肌无力患者,应确认肌炎诊断是否正确或是否存在其他潜在肌肉疾病。
- 确认组织持续炎症后,应制定调整治疗的策略,并可参考自身抗体分型。
局限性
- 指导治疗策略的对照试验很少。
- 自身抗体分型指导治疗的观点主要来自开放研究和病例系列。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The idiopathic inflammatory myopathies (IIMs) are chronic disorders characterized by inflammation in skeletal muscle but also in other organs such as the skin, lungs, joints, gastrointestinal tract, and heart. The effect of immunosuppressive treatment varies between individual patients and between organ manifestations within the same individual. Many patients respond poorly to first-line treatment with glucocorticoids and other immunosuppressive agents such as methotrexate or azathioprine, with symptoms persisting in the muscles, skin, and lungs, leading to refractory disease. Management of refractory IIM is a clinical challenge, and a systematic approach is proposed to better understand the lack of treatment response, in order to guide disease management. The first step in the management of refractory IIM is to recognize whether remaining symptoms are caused by persistent inflammation in the affected tissue or whether the symptoms may be attributable to damage preceding inflammation. Thus, a second diagnostic examination is recommended. Second, in particular for patients with remaining muscle weakness, it is important to ascertain whether the diagnosis of myositis is correct or whether another underlying muscle disorder could explain the symptoms. Third, with confirmation of remaining inflammation in the tissues, a strategy to change treatment needs to be undertaken. Few controlled trials are available to guide our treatment strategies. Furthermore, different subgroups of patients may benefit from different therapies, and different organ manifestations may respond to different therapies. In this context, subgrouping of patients with IIM based on autoantibody profile may be helpful, as there are emerging data from open studies and case series to support the notion of a varying treatment response in different autoantibody-defined subgroups of IIM patients.
引用
- Lundberg IE. Expert Perspective: Management of Refractory Inflammatory Myopathy. Arthritis Rheumatol. 2021. PMID: 33844450. doi:10.1002/art.41762
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。